인간 면역글로불린 시장(2026-2030년)

The global human immunoglobulin market is forecasted to grow by USD 6853.6 mn during 2025-2030, accelerating at a CAGR of 6.5% during the forecast period. The report on the global human immunoglobulin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of immunodeficiency and autoimmune disorders, advancements in plasma collection and fractionation technologies, shift toward patient-centric delivery modalities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global human immunoglobulin market is segmented as below:

By Application

• Autoimmune disorders
• Hematology diseases
• Inflammatory diseases
• Infectious diseases
• Others

By End-User

• Hospitals
• Clinics
• ASCs

By Form Factor

• Liquid
• Lyophilized

By Product Type

• IVIG
• SCIG

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the shift toward patient-centric home-based administration as one of the prime reasons driving the global human immunoglobulin market growth during the next few years. Also, expansion of clinical indications and precision medicine and innovations in plasma collection and manufacturing efficiency will lead to sizable demand in the market.

The report on the global human immunoglobulin market covers the following areas:

• Global human immunoglobulin market sizing
• Global human immunoglobulin market forecast
• Global human immunoglobulin market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global human immunoglobulin market vendors that include ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., Boya Bio pharmaceutical Group, CSL Behring, Emergent BioSolutions Inc., GC Biopharma Corp., Grifols SA, Hualan Biological Engineering Inc, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion SpA, KM Biologics Co. Ltd., LFB SA, Octapharma AG, Prothya Biosolutions, RAAS Corp., Reliance Life Sciences Pvt. Ltd., SK Plasma Co. Ltd., Taibang Biological Group Co. Ltd., Takeda Pharmaceutical Ltd., Virchow Biotech Pvt. Ltd.. Also, the global human immunoglobulin market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Form Factor
  • Executive Summary - Chart on Market Segmentation by Product Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Human Immunoglobulin Market 2020 - 2024
  • Historic Market Size - Data Table on Global Human Immunoglobulin Market 2020 - 2024 ($ million)
• 5.2 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.3 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.4 Form Factor segment analysis 2020 - 2024
  • Historic Market Size - Form Factor Segment 2020 - 2024 ($ million)
• 5.5 Product Type segment analysis 2020 - 2024
  • Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
• 5.6 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.7 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global human immunoglobulin market
• 6.2 Impact of geopolitical conflicts on global human immunoglobulin market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Application

• 8.1 Market segments
• 8.2 Comparison by Application
• 8.3 Autoimmune disorders - Market size and forecast 2025-2030
• 8.4 Hematology diseases - Market size and forecast 2025-2030
• 8.5 Inflammatory diseases - Market size and forecast 2025-2030
• 8.6 Infectious diseases - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Hospitals - Market size and forecast 2025-2030
• 9.4 Clinics - Market size and forecast 2025-2030
• 9.5 ASCs - Market size and forecast 2025-2030
• 9.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Market Segmentation by Form Factor

• 10.1 Market segments
• 10.2 Comparison by Form Factor
• 10.3 Liquid - Market size and forecast 2025-2030
• 10.4 Lyophilized - Market size and forecast 2025-2030
• 10.5 Market opportunity by Form Factor
  • Market opportunity by Form Factor ($ million)

11 Market Segmentation by Product Type

• 11.1 Market segments
• 11.2 Comparison by Product Type
• 11.3 IVIG - Market size and forecast 2025-2030
• 11.4 SCIG - Market size and forecast 2025-2030
• 11.5 Market opportunity by Product Type
  • Market opportunity by Product Type ($ million)

12 Customer Landscape

• 12.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

13 Geographic Landscape

• 13.1 Geographic segmentation
• 13.2 Geographic comparison
• 13.3 North America - Market size and forecast 2025-2030
  • 13.3.1 US - Market size and forecast 2025-2030
  • 13.3.2 Canada - Market size and forecast 2025-2030
  • 13.3.3 Mexico - Market size and forecast 2025-2030
• 13.4 Europe - Market size and forecast 2025-2030
  • 13.4.1 Germany - Market size and forecast 2025-2030
  • 13.4.2 France - Market size and forecast 2025-2030
  • 13.4.3 UK - Market size and forecast 2025-2030
  • 13.4.4 Italy - Market size and forecast 2025-2030
  • 13.4.5 Spain - Market size and forecast 2025-2030
  • 13.4.6 Russia - Market size and forecast 2025-2030
• 13.5 Asia - Market size and forecast 2025-2030
  • 13.5.1 China - Market size and forecast 2025-2030
  • 13.5.2 Japan - Market size and forecast 2025-2030
  • 13.5.3 India - Market size and forecast 2025-2030
  • 13.5.4 South Korea - Market size and forecast 2025-2030
  • 13.5.5 Thailand - Market size and forecast 2025-2030
  • 13.5.6 Taiwan - Market size and forecast 2025-2030
• 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 13.6.1 Brazil - Market size and forecast 2025-2030
  • 13.6.2 Australia - Market size and forecast 2025-2030
  • 13.6.3 Saudi Arabia - Market size and forecast 2025-2030
  • 13.6.4 South Africa - Market size and forecast 2025-2030
  • 13.6.5 Argentina - Market size and forecast 2025-2030
  • 13.6.6 UAE - Market size and forecast 2025-2030
  • 13.6.7 Chile - Market size and forecast 2025-2030
  • 13.6.8 Turkey - Market size and forecast 2025-2030
• 13.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

14 Drivers, Challenges, and Opportunity

• 14.1 Market drivers
  • Rising prevalence of immunodeficiency and autoimmune disorders
  • Advancements in plasma collection and fractionation technologies
  • Shift toward patient-centric delivery modalities
• 14.2 Market challenges
  • Dependence on human plasma supply constraints
  • Complex regulatory requirements and quality standards
  • High manufacturing costs and reimbursement pressures
• 14.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 14.4 Market opportunities
  • Shift toward patient-centric home-based administration
  • Expansion of clinical indications and precision medicine
  • Innovations in plasma collection and manufacturing efficiency

15 Competitive Landscape

• 15.1 Overview
• 15.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 15.3 Landscape disruption
  • Overview on factors of disruption
• 15.4 Industry risks
  • Impact of key risks on business

16 Competitive Analysis

• 16.1 Companies profiled
  • Companies covered
• 16.2 Company ranking index
  • Company ranking index
• 16.3 Market positioning of companies
  • Matrix on companies position and classification
• 16.4 ADMA Biologics Inc.
  • ADMA Biologics Inc. - Overview
  • ADMA Biologics Inc. - Business segments
  • ADMA Biologics Inc. - Key offerings
  • ADMA Biologics Inc. - Segment focus
  • SWOT
• 16.5 Bharat Serums and Vaccines Ltd.
  • Bharat Serums and Vaccines Ltd. - Overview
  • Bharat Serums and Vaccines Ltd. - Product / Service
  • Bharat Serums and Vaccines Ltd. - Key offerings
  • SWOT
• 16.6 Boya Bio pharmaceutical Group
  • Boya Bio pharmaceutical Group - Overview
  • Boya Bio pharmaceutical Group - Product / Service
  • Boya Bio pharmaceutical Group - Key offerings
  • SWOT
• 16.7 CSL Behring
  • CSL Behring - Overview
  • CSL Behring - Product / Service
  • CSL Behring - Key offerings
  • SWOT
• 16.8 Emergent BioSolutions Inc.
  • Emergent BioSolutions Inc. - Overview
  • Emergent BioSolutions Inc. - Product / Service
  • Emergent BioSolutions Inc. - Key offerings
  • SWOT
• 16.9 GC Biopharma Corp.
  • GC Biopharma Corp. - Overview
  • GC Biopharma Corp. - Business segments
  • GC Biopharma Corp. - Key offerings
  • GC Biopharma Corp. - Segment focus
  • SWOT
• 16.10 Grifols SA
  • Grifols SA - Overview
  • Grifols SA - Business segments
  • Grifols SA - Key offerings
  • Grifols SA - Segment focus
  • SWOT
• 16.11 Hualan Biological Engineering Inc
  • Hualan Biological Engineering Inc - Overview
  • Hualan Biological Engineering Inc - Business segments
  • Hualan Biological Engineering Inc - Key offerings
  • Hualan Biological Engineering Inc - Segment focus
  • SWOT
• 16.12 Intas Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd. - Overview
  • Intas Pharmaceuticals Ltd. - Product / Service
  • Intas Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 16.13 Kamada Ltd.
  • Kamada Ltd. - Overview
  • Kamada Ltd. - Business segments
  • Kamada Ltd. - Key offerings
  • Kamada Ltd. - Segment focus
  • SWOT
• 16.14 LFB SA
  • LFB SA - Overview
  • LFB SA - Product / Service
  • LFB SA - Key offerings
  • SWOT
• 16.15 SK Plasma Co. Ltd.
  • SK Plasma Co. Ltd. - Overview
  • SK Plasma Co. Ltd. - Product / Service
  • SK Plasma Co. Ltd. - Key offerings
  • SWOT
• 16.16 Taibang Biological Group Co. Ltd.
  • Taibang Biological Group Co. Ltd. - Overview
  • Taibang Biological Group Co. Ltd. - Product / Service
  • Taibang Biological Group Co. Ltd. - Key offerings
  • SWOT
• 16.17 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT
• 16.18 Virchow Biotech Pvt. Ltd.
  • Virchow Biotech Pvt. Ltd. - Overview
  • Virchow Biotech Pvt. Ltd. - Product / Service
  • Virchow Biotech Pvt. Ltd. - Key offerings
  • SWOT

17 Appendix

• 17.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 17.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 17.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 17.4 Research methodology
  • Research methodology
• 17.5 Data procurement
  • Information sources
• 17.6 Data validation
  • Data validation
• 17.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 17.8 Data synthesis
  • Data synthesis
• 17.9 360 degree market analysis
  • 360 degree market analysis
• 17.10 List of abbreviations
  • List of abbreviations